PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Status:
Recruiting
Trial end date:
2028-01-30
Target enrollment:
Participant gender:
Summary
This randomized trial will evaluate the efficacy and safety of PRGN-2009 in combination with
pembrolizumab compared to pembrolizumab alone in patients with pembrolizumab-resistant
recurrent or metastatic cervical cancer.